No headlines found.
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
Globe Newswire (Wed, 28-Jan 10:00 AM ET)
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.
As of April 22, 2026, GDTC stock price declined to $1.00 with 6,497 million shares trading.
GDTC has a beta of 0.42, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.01 to the broad based SPY ETF.
GDTC has a market cap of $11.83 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GDTC traded as high as $9.25 and as low as $.73.
GDTC has underperformed the market in the last year with a price return of -57.1% while the SPY ETF gained +36.3%. However, in the short term, GDTC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.2% vs +3.5% return in SPY. But in the last 2 weeks, GDTC shares have been beat by the market, returning 0.0% compared to an SPY return of +5.2%.
GDTC support price is $.97 and resistance is $1.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.
